18076-61-4

Basic information

• Product Name: 1H-benzotriazol-4-amine
• Synonyms: 1H-benzotriazol-4-amine;1H-1,2,3-benzotriazol-4-amine hydrochloride;Einecs 241-982-2;1H-1,2,3-benzotriazol-4-amine(SALTDATA: HCl 0.4H2O);1H-benzo[d][1,2,3]triazol-4-amine hydrochloride;2H-Benzotriazol-4-ylamine
• CAS NO: 18076-61-4
• Molecular Formula: C₆H₆N₄
• Molecular Weight: 134.13864
• EINECS: 241-982-2
• Mol File: 18076-61-4.mol

Chemical Properties

• Melting Point: 148-150°
• Boiling Point: 387.4°Cat760mmHg
• Flash Point: 216.5°C
• Appearance: /
• Density: 1.48g/cm³
• Vapor Pressure: 3.29E-06mmHg at 25°C
• Refractive Index: 1.806
• CAS DataBase Reference: 1H-benzotriazol-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-benzotriazol-4-amine(18076-61-4)
• EPA Substance Registry System: 1H-benzotriazol-4-amine(18076-61-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 18076-61-4(Hazardous Substances Data)

Usage

Uses

Used in Industrial Applications:
1H-benzotriazol-4-amine is used as a corrosion inhibitor for protecting metal surfaces from degradation caused by exposure to air and moisture. It forms a protective layer on metal surfaces, preventing corrosion and extending the life of metal components.
1H-benzotriazol-4-amine is also used as an anti-oxidant in the production of fuels, lubricants, and metalworking fluids. It helps to prevent the oxidation of these materials, thereby improving their performance and extending their shelf life.
Used in Plastics and Polymers Production:
In the plastics and polymers industry, 1H-benzotriazol-4-amine is used as a stabilizer to extend the shelf life and improve the thermal stability of these materials. It helps to prevent the degradation of plastics and polymers during processing and storage, ensuring their quality and performance.
Used in Pharmaceutical Research:
1H-benzotriazol-4-amine is being studied for its potential therapeutic applications, including as an anti-cancer and anti-viral agent. Its unique chemical structure and properties make it a promising candidate for the development of new drugs and therapies.
However, it is important to note that the use and production of 1H-benzotriazol-4-amine are strictly regulated due to its potential environmental and health hazards. Proper handling, storage, and disposal measures must be taken to minimize any risks associated with its use.

InChI:InChI=1/C6H6N4/c7-4-2-1-3-5-6(4)9-10-8-5/h1-3H,7H2,(H,8,9,10)

Upstream product

• 6299-39-4 4-nitro-1H-benzotriazole 
• 1228575-46-9 7-bromo-4-nitro-1H-benzotriazole 
• 95-14-7 1,2,3-Benzotriazole 
• 136-85-6 5⁽⁶⁾-methylbenzotriazole 
• 31995-60-5 5-methyl-4-nitrobenzotriazole 

Downstream Products

• 26725-51-9 4-hydroxybenzotriazole 
• 945396-69-0 N'-(1H-benzotriazol-4-yl)-N-(3,5-dimorpholin-4-ylphenyl)pyrimidine-2,4-diamine 
• 137434-68-5 4-<(p-toluenesulfonyl)amino>-1-(p-toluenesulfonyl)benzotriazole 
• 137434-62-9 4-<(benzenesulfonyl)amino>-1-(p-toluenesulfonyl)benzotriazole 
• 137434-67-4 1-(benzenesulfonyl)-4-<(p-toluenesulfonyl)amino>benzotriazole 
• 128531-18-0 4-Amino-2-<2'-deoxy-3',5'-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl>-2H-benzotriazole 
• 128531-19-1 4-Amino-3-<2'-deoxy-3',5'-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl>-3H-benzotriazole 
• 128531-17-9 4-Amino-1-<2'-deoxy-3',5'-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl>-1H-benzotriazole 
• 137434-66-3 4-<(p-toluenesulfonyl)amino>benzotriazole 
• 137434-63-0 4-<(benzenesulfonyl)amino>-1-(benzenesulfonyl)benzotriazole 

Relevant articles and documents

4-N-BENZAZOLYLAMINO DERIVATIVES OF 3-Y-3-BUTEN-2-ONE

Ethoxymethylene derivatives of 2,4-pentanedione (Ia), 3-oxobutanenitrile (Ib), methyl (Ic) or ethyl (Id) 3-oxobutanoate give with 4- or 5-aminobenzimidazole or benzotriazole, respectively, under mild conditions products of nucleophilic substitution II-V.Structure of these compounds was discussed on the basis of their spectral measurements -IR, UV, 1H, 13C NMR and mass spectra.

Synthesis of N-aryl and N-heteroaryl hydroxylamines via partial reduction of nitroarenes with soluble nanoparticle catalysts

Polystyrene-supported ruthenium nanoparticles enable the selective hydrazine-mediated reduction of nitroarenes to hydroxylamine products in high yield and selectivity. Key to obtaining the hydroxylamine product in good yield was the use of organic solvents capable of solubilizing the polystyrene-supported nanoparticle catalyst. N-aryl and N-heteroaryl hydroxylamines are generated under exceptionally mild conditions and in the presence of a various easily reduced functional groups.

3, 4-DI-SUBSTITUTED CYCLOBUTENE- 1, 2 -DIONES AS CXCR2 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula (I) wherein R1, R2, Ar, p, R4 and R5 are as defined herein, which are useful for creating diseases which respond to CXCR2 receptor mediators. Pharmaceutical

JNK MODULATORS

Compounds of formula I modulate JNK: wherein X1 and X2 are each simultaneously N or CH;X3 is CH—R2 or N—SO2R, where R is lower alkyl;R1 is aryl or heteroaryl, substituted with 0-3 lower alkyl radicals;R2 is where R3 is H, lower acyl, or an amino acid, or a pharmaceutically acceptable salt thereof.

THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).

ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

IL-8 receptor antagonists

This invention relates to novel benzo-2-triazole substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GROα, GROβ, GROγ and NAP-2 mediated diseases.